Table 2.
Personal characteristics and clinical features of 80 patients affected by atopic dermatitis treated with dupilumab during the COVID-19 pandemic
| Patient characteristics | ||
|---|---|---|
| Response rate, n (%) | 59 | 73.8% |
| Sex, n (%) | ||
| Men | 39 | 48.8% |
| Women | 41 | 51.2% |
| Age, median [range] | 31.5 [18–89] y | |
| EASI (last assessment before lockdown), mean ± SD | 9.10 ± 11.27 | |
| High SARS-CoV-2 burden geographical setting, n (%) | 12 | 15% |
| Comorbidities, n (%) | ||
| Asthma and airway disease | 36 | 45% |
| Cardiometabolic disorders | 3 | 3.8% |
| both | 1 | 1.2% |
| TOTAL | 40 | 50% |
| Treatment interruption, n (%) | ||
| Personal decision | 5 | 6.3% |
| Difficulty consulting physician | 1 | 1.2% |
| Difficulty drug supplies | 1 | 1.2% |
| TOTAL | 7 | 8.8% |
| Flu-like symptoms, n (%) | 7 | 8.8% |
| Fever >37.5°C, n (%) | 2 | 2.5% |
| Symptom duration, n (%) | ||
| ˂1 wk | 5 | 6.3% |
| 7-14 d | 1 | 1.2% |
| ˃14 d | 1 | 1.2% |
| Positive SARS-CoV-2 PCR, n (%) | 1 | 1.2% |
COVID-19, coronavirus disease 2019; EASI, eczema area and severity index; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.